Paolo Calabrò

18.7k total citations · 2 hit papers
298 papers, 7.4k citations indexed

About

Paolo Calabrò is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Epidemiology. According to data from OpenAlex, Paolo Calabrò has authored 298 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 192 papers in Cardiology and Cardiovascular Medicine, 98 papers in Surgery and 47 papers in Epidemiology. Recurrent topics in Paolo Calabrò's work include Antiplatelet Therapy and Cardiovascular Diseases (55 papers), Acute Myocardial Infarction Research (41 papers) and Cardiovascular Function and Risk Factors (38 papers). Paolo Calabrò is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (55 papers), Acute Myocardial Infarction Research (41 papers) and Cardiovascular Function and Risk Factors (38 papers). Paolo Calabrò collaborates with scholars based in Italy, United States and United Kingdom. Paolo Calabrò's co-authors include Edward T.H. Yeh, James T. Willerson, Giuseppe Limongelli, Felice Gragnano, Raffaele Calabrò, Enrica Golia, Maria Giovanna Russo, Paolo Golino, Arturo Cesaro and Fabio Fimiani and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Paolo Calabrò

278 papers receiving 7.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target

2014 429 citations Enrica Golia, Giuseppe Limongelli et al. profile →
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry

2022 125 citations Arturo Cesaro, Felice Gragnano et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paolo Calabrò Italy	45	3.6k	1.6k	1.5k	1.3k	953	298	7.4k
Ignatios Ikonomidis Greece	45	4.2k 1.2×	1.3k 0.8×	1.5k 1.0×	846 0.7×	734 0.8×	309	7.4k
Alexios S. Antonopoulos Greece	40	3.0k 0.8×	1.6k 1.0×	1.3k 0.9×	1.3k 1.1×	815 0.9×	198	7.0k
Christoph Bickel Germany	44	2.8k 0.8×	1.8k 1.1×	1.7k 1.2×	1.4k 1.1×	650 0.7×	107	7.6k
Gerasimos Siasos Greece	48	3.0k 0.8×	1.6k 1.0×	973 0.7×	1.9k 1.5×	925 1.0×	414	8.1k
John Lekakis Greece	50	4.6k 1.3×	1.5k 0.9×	1.0k 0.7×	908 0.7×	1.0k 1.1×	248	8.2k
Per Tornvall Sweden	44	3.4k 0.9×	1.8k 1.1×	852 0.6×	658 0.5×	941 1.0×	185	6.8k
Masanori Emoto Japan	52	2.9k 0.8×	1.4k 0.9×	1.3k 0.9×	1.0k 0.8×	2.3k 2.4×	258	8.7k
Joseph P. McConnell United States	42	2.0k 0.6×	3.0k 1.8×	1.7k 1.1×	1.4k 1.1×	1.4k 1.5×	109	7.9k
Stefania Basili Italy	51	2.4k 0.7×	1.5k 0.9×	2.0k 1.4×	1.0k 0.8×	716 0.8×	242	8.2k
Jaw‐Wen Chen Taiwan	51	2.8k 0.8×	1.6k 1.0×	1.1k 0.8×	3.1k 2.4×	993 1.0×	291	9.4k

Countries citing papers authored by Paolo Calabrò

Since Specialization

Citations

This map shows the geographic impact of Paolo Calabrò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paolo Calabrò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paolo Calabrò more than expected).

Fields of papers citing papers by Paolo Calabrò

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paolo Calabrò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paolo Calabrò. The network helps show where Paolo Calabrò may publish in the future.

Co-authorship network of co-authors of Paolo Calabrò

This figure shows the co-authorship network connecting the top 25 collaborators of Paolo Calabrò. A scholar is included among the top collaborators of Paolo Calabrò based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paolo Calabrò. Paolo Calabrò is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laudani, Claudio, Davide Capodanno, Felice Gragnano, et al.. (2025). Factor XI Inhibitors or Direct Oral Anticoagulants in Atrial Fibrillation: A Focused Meta-analysis. Thrombosis and Haemostasis. 1 indexed citations

Cacciatore, Stefano, Marco Bernardi, Luigi Spadafora, et al.. (2025). Chronic Inflammatory Diseases and Cardiovascular Risk: Current Insights and Future Strategies for Optimal Management. International Journal of Molecular Sciences. 26(7). 3071–3071. 5 indexed citations

Gragnano, Felice, et al.. (2025). Long-term antiplatelet monotherapy after PCI: searching for the smart choice. European Heart Journal - Cardiovascular Pharmacotherapy. 11(4). 322–322.

Vetrano, Erica, Raffaele Galiero, Vittorio Simeon, et al.. (2025). Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study. Pharmaceuticals. 18(8). 1200–1200.

Costa, Francesco, Juan José Gómez‐Doblas, Marianna Adamo, et al.. (2025). Artificial intelligence in cardiovascular pharmacotherapy: applications and perspectives. European Heart Journal. 46(37). 3616–3627. 1 indexed citations

Marra, Alberto M., Giuseppe Palmiero, Maria Angela Losi, et al.. (2024). Exercise Training and Rehabilitation in Cardiac Amyloidosis (ERICA) Study. Heart Failure Clinics. 20(3). e55–e62.

Gragnano, Felice, G. Verde, Arturo Cesaro, et al.. (2024). Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions. International Journal of Cardiology. 422. 132921–132921. 1 indexed citations

Rinaldi, Riccardo, Giulia La Vecchia, Alice Bonanni, et al.. (2023). MINOCA Associated with a Myocardial Bridge: Pathogenesis, Diagnosis and Treatment. Journal of Clinical Medicine. 12(11). 3799–3799. 10 indexed citations

Cesaro, Arturo, Erica Vetrano, Giovanni Signore, et al.. (2023). Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice. International Journal of Molecular Sciences. 24(9). 8099–8099. 8 indexed citations

10.

Rubino, Marta, Emanuele Monda, Martina Caiazza, et al.. (2022). Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference. SHILAP Revista de lepidopterología. 12(1). 102–108. 1 indexed citations

11.

Mennitti, Cristina, Annaluisa Ranieri, Ersilia Nigro, et al.. (2022). The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers. International Journal of Environmental Research and Public Health. 20(1). 602–602. 4 indexed citations

12.

Gragnano, Felice, Giuseppe Gargiulo, Arturo Cesaro, et al.. (2022). Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice. Journal of Clinical Medicine. 11(21). 6246–6246. 5 indexed citations

13.

Amodio, Federica, Martina Caiazza, Fabio Fimiani, Paolo Calabrò, & Giuseppe Limongelli. (2021). MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. SHILAP Revista de lepidopterología. 11(4). 230–254. 3 indexed citations

14.

Monda, Emanuele, Giuseppe Palmiero, Marta Rubino, et al.. (2020). Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies. International Journal of Molecular Sciences. 21(18). 6462–6462. 44 indexed citations

15.

Brancaccio, Mariarita, Cristina Mennitti, Sonia Laneri, et al.. (2020). Methicillin-Resistant Staphylococcus aureus: Risk for General Infection and Endocarditis Among Athletes. Antibiotics. 9(6). 332–332. 11 indexed citations

16.

Brancaccio, Mariarita, Cristina Mennitti, Arturo Cesaro, et al.. (2020). Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. International Journal of Environmental Research and Public Health. 17(24). 9424–9424. 29 indexed citations

17.

Russo, Vincenzo, Anna Rago, Riccardo Proietti, et al.. (2019). Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study. BioMed Research International. 2019. 1–6. 7 indexed citations

18.

Gragnano, Felice, Simona Sperlongano, Enrica Golia, et al.. (2017). The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators of Inflammation. 2017. 1–13. 168 indexed citations

19.

Gragnano, Felice, Mario Crisci, Maurizio Cappelli Bigazzi, et al.. (2017). Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. Angiology. 69(2). 103–112. 8 indexed citations

20.

Calabrò, Paolo, Enrica Golia, & Edward T.H. Yeh. (2011). Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches. Current Pharmaceutical Biotechnology. 13(1). 4–16. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact